Anaphylaxis Food Clinical Trial
— PrePAREOfficial title:
Transepidermal Water Loss as a Predictor for Severe Allergic Reactions in Oral Food Challenges
NCT number | NCT05696236 |
Other study ID # | HUM00205852 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 23, 2023 |
Est. completion date | March 2027 |
This research study is testing a new way to look for the early stages of anaphylaxis. Eligible participants will have a small monitor (transepidermal water loss) placed on the forearm during a food challenge (for peanut allergies). This monitor continuously records the amount of water lost through the skin. In a previous study the team learned what values are associated with an anaphylactic reaction. These values are called "stopping rules." This study is looking at whether it can use these new stopping rules to end the oral food challenge before a person may show any symptoms.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | March 2027 |
Est. primary completion date | March 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Months to 5 Years |
Eligibility | Inclusion Criteria: - Have a known history of food anaphylaxis to peanut confirmed by an allergist - Have had skin and blood food allergy testing to peanut within the past 12 months. Meet the 80% likelihood positive predictive value threshold for peanut allergy based on at least 1 of either the skin or blood immunoglobulin E (IgE) tests per current literature corrected for age. - Meet all clinical oral food challenge (OFC) requirements. This includes no asthma or atopic dermatitis exacerbations, no recent viral infections, no recent antibiotics, and no food allergy reactions in the past month. Exclusion Criteria: - Any known cardiovascular disease, cancer, pulmonary disease except well-controlled asthma, or other condition that would preclude an OFC otherwise. - Any medication use that would interfere with an OFC result. Medications in this category include antihistamines (first or second generation) within 1 week, omalizumab within 3 months, and others listed in the protocol appendix. - Any skin condition aside from well-controlled eczema that might impact TEWL measurement, including such conditions as autoimmune skin conditions (such as psoriasis), congenital ichthyoses, hyper-IgE syndromes. |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
Lead Sponsor | Collaborator |
---|---|
University of Michigan | The Gerber Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Anaphylaxis occurrence rates in each group | Any Brighton Level 1, 2, or 3 anaphylaxis. | Approximately 4-6 hours (Day 1 during the food challenge) | |
Secondary | Reaction rates in each group | Any objective symptom of allergic reaction occurs (e.g., hives, angioedema, vomiting, wheeze, etc) not rising to the definition of anaphylaxis. | Approximately 4-6 hours (Day 1 during the food challenge) | |
Secondary | Anaphylaxis severity in each group | This will be graded on a scale of 1 to 5 (where 1 = mild, 5 = death)) according to criteria set forth in the Consortium for Food Allergy Research (CoFAR) Grading Scale. | Approximately 4-6 hours (Day 1 during the food challenge) | |
Secondary | Anaphylaxis likelihood in each group based on the Brighton score | The Brighton score gives a 0-3 score of anaphylaxis likelihood (0 = no anaphylaxis, 3 = highly likely). | Approximately 4-6 hours (Day 1 during the food challenge) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03487315 -
Major Allergen in Wheat Anaphylaxis in Thai Population
|
N/A | |
Completed |
NCT03149315 -
Inhibition of Anaphylaxis by Ibrutinib
|
Phase 2 |